Rohto Pharmaceutical Co Ltd
TSE:4527
Intrinsic Value
Rohto Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, cosmetics, and functional food items. [ Read More ]
The intrinsic value of one
Rohto Pharmaceutical Co Ltd
stock under the Base Case scenario is
3 273.71
JPY.
Compared to the current market price of 2 983 JPY,
Rohto Pharmaceutical Co Ltd
is
Undervalued by 9%.
Rohto Pharmaceutical Co Ltd's market capitalization is 680.5B JPY.
Rohto Pharmaceutical Co Ltd stock price is 2 983 JPY.
Rohto Pharmaceutical Co Ltd stock price (2983 JPY) is 9% less than its Intrinsic Value (3 273.71 JPY).
Rohto Pharmaceutical Co Ltd stock price (2983 JPY) is 20% less than its DCF Value (3 709.06 JPY). Open DCF Valuation
Rohto Pharmaceutical Co Ltd stock (2 838.36 JPY) is 5% less than its price (2983 JPY). Open Relative Valuation
Rohto Pharmaceutical Co Ltd has upside potential of 37% compared to the average analyst price target.
Open Wall St Estimates
Rohto Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Rohto Pharmaceutical Co Ltd's ROE (Return on Equity) has increased in the last 3 years from 11% to 14%.
Rohto Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 14%.
Rohto Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
Rohto Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 11% to 14%.
Rohto Pharmaceutical Co Ltd's Revenue has grown by 14% over the past 12 months.
Rohto Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Rohto Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 13%. The company is efficient at transforming stockholders' equity into net income.
Rohto Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
Rohto Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 10% per year over the next 3 years.
Rohto Pharmaceutical Co Ltd's Revenue has been growing by 14% per year for the last 3 years.
Rohto Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Rohto Pharmaceutical Co Ltd's short-term assets (214B JPY) exceed its short-term liabilties (84B JPY).
Rohto Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Rohto Pharmaceutical Co Ltd's long-term assets (342B JPY) exceed its long-term liabilties (102B JPY).
Rohto Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.02.
Rohto Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (82B JPY) than debt (5B JPY).
Rohto Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 5.98.
Rohto Pharmaceutical Co Ltd earns more than enough operating income (41B JPY) to safely cover interest payments on its debt (234m JPY).
Valuation Backtest
Rohto Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Rohto Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Rohto Pharmaceutical Co Ltd
Balance Sheet Decomposition
Rohto Pharmaceutical Co Ltd
| Current Assets | 214.2B |
| Cash & Short-Term Investments | 81.9B |
| Receivables | 73B |
| Other Current Assets | 59.3B |
| Non-Current Assets | 128B |
| Long-Term Investments | 41.2B |
| PP&E | 68.4B |
| Intangibles | 9.1B |
| Other Non-Current Assets | 9.2B |
| Current Liabilities | 83.6B |
| Accounts Payable | 22.4B |
| Accrued Liabilities | 22.8B |
| Other Current Liabilities | 38.4B |
| Non-Current Liabilities | 18.5B |
| Long-Term Debt | 5.3B |
| Other Non-Current Liabilities | 13.2B |
Earnings Waterfall
Rohto Pharmaceutical Co Ltd
|
Revenue
|
263.6B
JPY
|
|
Cost of Revenue
|
-110.2B
JPY
|
|
Gross Profit
|
153.4B
JPY
|
|
Operating Expenses
|
-112.8B
JPY
|
|
Operating Income
|
40.6B
JPY
|
|
Other Expenses
|
-9.7B
JPY
|
|
Net Income
|
30.9B
JPY
|
Free Cash Flow Analysis
Rohto Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Rohto Pharmaceutical Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Rohto Pharmaceutical Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Rohto Pharmaceutical Co Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Score
Rohto Pharmaceutical Co Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Rohto Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Rohto Pharmaceutical Co Ltd
is 4 095.87 JPY
with a low forecast of 3 403.7 JPY and a high forecast of 4 725 JPY.
Shareholder Return
Price
Rohto Pharmaceutical Co Ltd
| Average Annual Return | -4.96% |
| Standard Deviation of Annual Returns | 21.93% |
| Max Drawdown | -54% |
| Market Capitalization | 680.5B JPY |
| Shares Outstanding | 228 798 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Rohto Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Rohto Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products, cosmetics, and functional food items. The company is headquartered in Osaka, Osaka-Fu and currently employs 6,596 full-time employees. The firm primarily provides eye care-related products, including eye drops and eye lotions; skin care-related products, including dermatological preparations, lip balms, sunscreens and functional cosmetics; oral medication and food-related products, including digestive medicines, Chinese herbal medicines and supplements, as well as extracorporeal test drugs and other products. The firm operates its business in domestic market and overseas markets, including Europe, Asia and America.
Contact
IPO
Employees
Officers
The intrinsic value of one
Rohto Pharmaceutical Co Ltd
stock under the Base Case scenario is
3 273.71
JPY.
Compared to the current market price of 2 983 JPY,
Rohto Pharmaceutical Co Ltd
is
Undervalued by 9%.
You don't have any saved screeners yet
